Complement-Based Drug Development Summit on December 01-03, 2025 in Boston, United States

So far, 2025 has brought significant excitement and progress to the complement-based therapeutic landscape. Leading biopharma companies like Novartis, Annexon Biosciences and Omeros, are making significant clinical progress in PNH, AMD, IgAN and C3G, whilst key academics such as Michael Holers, Michael Brenner, and Brahm Segal continue to make discoveries in complement imaging, novel pathways, and new therapeutics areas such as oncology and transplantation.

The Complement-Based Drug Development Summit returns for its 9th year to unite the leading experts in complement biology and therapeutic development, from innovative biotech to impactful large pharma and academic experts. This meeting will harness the energy and dedication deepening the current understanding of the complement system to advance drug development in rare disease and beyond with patients at the forefront.

Join us at the 2025 meeting to gain insights from 20+ expert speakers covering the end-to-end complement-based drug development, from basic biology to diagnostics and clinical development.

Participate in three dedicated workshops for active discussion on key topics including the intracellular complement system, bispecific complement mediators, and innovative delivery of complement-based therapeutics to ensure delivery to the correct targets.

This comprehensive program spans a broad spectrum of renal, ophthalmic, neurological, and haematological indications, mirroring the shift in focus of the complement field from rare orphan indications to larger patient populations.

Join 80+ industry experts this December and access exclusive insights into therapeutic development across the complement field and bring actionable learnings and competitive intelligence back to your team.

URLs:

Tickets: https://go.evvnt.com/3191219-2?pid=10008

Brochure: https://go.evvnt.com/3191219-3?pid=10008

Time: 8:00 AM - 4:40 PM

Prices:

Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 4197.00,

Drug Developer Pricing - 2 Day Pass (Conference Only) : USD 2999.00,

Academic Pricing - 3 Day Pass (Conference + Workshop Day): USD 3597.00,

Academic Pricing - 2 Day Pass (Conference Only): USD 2599.00,

Service Provider Pricing - 3 Day Pass (Conference + Workshop Day): USD 5097.00,

Service Provider Pricing - 2 Day Pass (Conference Only): USD 3699.00

Speakers: Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Baerbel Rohrer, Scientific Advisor, Cascade Biotechnologies, Ben Afzali, Section Chief - Immunoregulation Section, NIDDK, NIH, Brahm Segal, Chair of Internal Medicine, Moffitt Cancer Center, Carl Atkinson, Professor, Northwestern University, Dennis Keefe, Chief Scientific Officer, Complement Therapeutics, Dr Magnus Nicolson, MBA FRSM FRSC Chief Executive Officer, Invizius, Feng Lin, Researcher, Cleveland Clinic, Henk-Andre Kroon, Senior Vice President and Head of Translational Medicine, Annexon Biosciences, Inge Van de Walle, Research Fellow - Complement Lead, Argenx, Lori Taylor, Senior Vice President - Portfolio Strategy and Operations, Annexon Biosciences, Martin Kolev, Associate Director - Complement Science, Apellis, Michael Brenner, Professor - Medicine, Harvard Medical School, Michael Holers, Professor of Medicine and Immunology, University of Colorado, Michael Storek, Head of Complement Cluster, Sanofi, Niels Riedemann, Chief Executive Officer, Inflarx, Robert Macleod, Chief Scientific Officer, ADARx, Simon Clarke, Professor, University of Tübingen, Yuyan Jin, Senior Vice President and Head of Nonclincial and Clinical Development, SanegeneBio